Clinical Report: Efficacy of Perampanel as Monotherapy for Seizure Control
Overview
This study evaluates the efficacy of perampanel (PER) as a monotherapy for preventing intraoperative seizures (IOS) specifically during awake craniotomy (AC) in glioma patients.
Background
Awake craniotomy is a critical procedure for glioma resection, particularly in eloquent brain regions, as it allows for real-time functional mapping. However, intraoperative seizures pose significant risks, potentially leading to complications such as increased intracranial pressure and neurological deterioration. Effective seizure management during AC is essential for optimizing patient outcomes and minimizing postoperative deficits.
Data Highlights
No numerical data was provided in the article.
Key Findings
Intraoperative seizures occur in 3.4 to 24% of awake craniotomy cases.
Perampanel monotherapy was initiated at least 3 days before surgery at a dose of 2 mg.
Postoperative seizure outcomes were categorized into early (within a week) and late (up to 3 months) seizures.
Combination therapy with levetiracetam and perampanel was previously shown to reduce IOS compared to levetiracetam alone.
Patients with prior seizure history were excluded from this study to assess the efficacy of PER monotherapy.
Clinical Implications
Expand on how perampanel simplifies management protocols and detail potential adverse events associated with combination therapies.
Conclusion
Reiterate the need for further studies and specify the importance of larger cohorts to validate findings.
Novo Nordisk’s Parkinson’s cell therapy finds a new home at Cellular Intelligence, while base editing, prime editing, and large-insertion genome writing push forward
